Kymera Therapeutics (KYMR) Operating Expenses (2019 - 2026)

Kymera Therapeutics (KYMR) has 8 years of Operating Expenses data on file, last reported at $118.5 million in Q1 2026.

• Operating Expenses for Q1 2026 came in at $118.5 million, up 22.78% year-over-year; the trailing twelve-month figure through Mar 2026 was $410.6 million (up 21.8% YoY), and the FY2025 annual result was $388.6 million, up 25.88% from the prior year.
• Operating Expenses advanced to $118.5 million in Q1 2026 per KYMR's latest filing, from $100.8 million in the prior quarter.
• Over five years, Operating Expenses peaked at $118.5 million in Q1 2026 and troughed at $46.6 million in Q1 2022.
• A 5-year average of $74.6 million and a median of $68.1 million in 2024 frame the typical range for Operating Expenses.
• On a YoY basis, Operating Expenses climbed as much as 46.07% in 2022 and fell as far as 11.15% in 2022.
• A 5-year view of Operating Expenses shows it stood at $54.8 million in 2022, then climbed by 22.69% to $67.2 million in 2023, then soared by 31.18% to $88.1 million in 2024, then advanced by 14.31% to $100.8 million in 2025, then climbed by 17.62% to $118.5 million in 2026.
• Business Quant data shows KYMR's Operating Expenses at $118.5 million in Q1 2026, $100.8 million in Q4 2025, and $95.3 million in Q3 2025.